keyword
MENU ▼
Read by QxMD icon Read
search

Post metastasis prostate cancer

keyword
https://www.readbyqxmd.com/read/27862841/the-ubiquitin-ligase-ube4a-inhibits-prostate-cancer-progression-by-targeting-interleukin-like-emt-inducer-ilei
#1
Yanan Sun, Xiaopeng Jia, Qiang Gao, Xing Liu, Lianguo Hou
Epithelial to mesenchymal transition (EMT) is an important prerequisite for metastasis to secondary organs. Interleukin-like EMT inducer (ILEI) protein has been shown to translationally upregulated during EMT and metastatic progression as a consequence of aberrant TGF-β signaling. Our initial evaluation of FAM3C (encoding ILEI) and ILEI expression in normal prostate (PCS-440-010) and prostate cancer cell lines (DU145, LNCaP, and PC3) revealed detectable protein expression in only LNCaP cell line even though all cell lines tested had comparable FAM3C expression...
November 10, 2016: IUBMB Life
https://www.readbyqxmd.com/read/27770303/cabazitaxel-for-hormone-relapsed-metastatic-prostate-cancer-previously-treated-with-a-docetaxel-containing-regimen-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#2
Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Hamilton, Duncan Chambers, Mark Clowes, John Graham, M Satish Kumar
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures cabazitaxel (Jevtana(®), Sanofi, UK) to submit evidence for the clinical and cost effectiveness of cabazitaxel for treatment of patients with metastatic hormone-relapsed prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen. The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
October 22, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27745980/salvage-radiation-therapy-dose-response-for-biochemical-failure-of-prostate-cancer-after-prostatectomy-a-multi-institutional-observational-study
#3
Thomas M Pisansky, Shree Agrawal, Daniel A Hamstra, Bridget F Koontz, Stanley L Liauw, Jason A Efstathiou, Jeff M Michalski, Felix Y Feng, Matthew C Abramowitz, Alan Pollack, Mitchell S Anscher, Drew Moghanaki, Robert B Den, Kevin L Stephans, Anthony L Zietman, W Robert Lee, Michael W Kattan, Andrew J Stephenson, Rahul D Tendulkar
PURPOSE: To determine whether a dose-response relationship exists for salvage radiation therapy (RT) of biochemical failure after prostatectomy for prostate cancer. METHODS AND MATERIALS: Individual data from 1108 patients who underwent salvage RT at 10 academic centers were pooled. The cohort was enriched for selection criteria more likely associated with tumor recurrence in the prostate bed (margin positive and pre-RT prostate-specific antigen [PSA] level of ≤2...
December 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27743920/development-and-validation-of-a-24-gene-predictor-of-response-to-postoperative-radiotherapy-in-prostate-cancer-a-matched-retrospective-analysis
#4
Shuang G Zhao, S Laura Chang, Daniel E Spratt, Nicholas Erho, Menggang Yu, Hussam Al-Deen Ashab, Mohammed Alshalalfa, Corey Speers, Scott A Tomlins, Elai Davicioni, Adam P Dicker, Peter R Carroll, Matthew R Cooperberg, Stephen J Freedland, R Jeffrey Karnes, Ashley E Ross, Edward M Schaeffer, Robert B Den, Paul L Nguyen, Felix Y Feng
BACKGROUND: Postoperative radiotherapy has an important role in the treatment of prostate cancer, but personalised patient selection could improve outcomes and spare unnecessary toxicity. We aimed to develop and validate a gene expression signature to predict which patients would benefit most from postoperative radiotherapy. METHODS: Patients were eligible for this matched, retrospective study if they were included in one of five published US studies (cohort, case-cohort, and case-control studies) of patients with prostate adenocarcinoma who had radical prostatectomy (with or without postoperative radiotherapy) and had gene expression analysis of the tumour, with long-term follow-up and complete clinicopathological data...
October 12, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27730756/risk-of-skeletal-related-events-among-elderly-prostate-cancer-patients-by-site-of-metastasis-at-diagnosis
#5
Arif Hussain, Abdalla Aly, C Daniel Mullins, Yi Qian, Jorge Arellano, Eberechukwu Onukwugha
The purpose of this study was to estimate the risk of developing skeletal-related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients. We conducted a retrospective cohort study using linked SEER (Surveillance, Epidemiology, and End Results) and Medicare data and identified men over the age of 65 with incident metastatic prostate cancer diagnosed during 2005-2009. SREs included radiation (RAD), pathological fractures (PF), bone surgery (BS), and spinal cord compression (SCC)...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27683182/a-phase-ii-trial-of-abiraterone-combined-with-dutasteride-for-men-with-metastatic-castration-resistant-prostate-cancer
#6
Mary-Ellen Taplin, Rana R McKay, Lillian Werner, Elahe A Mostaghel, Rosina T Lis, Olga Voznesensky, Zhenwei Zhang, Brett Marck, Alvin M Matsumoto, Liran Domachevsky, Katherine A Zukotynski, Manoj K Bhasin, Glenn J Bubley, Bruce Montgomery, Philip W Kantoff, Steven P Balk
PURPOSE: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abiraterone and dutasteride. EXPERIMENTAL DESIGN: Eligible metastatic CRPC patients underwent a baseline metastasis biopsy. Patients received abiraterone and prednisone for two 4-week cycles...
September 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27681757/posttreatment-prostate-specific-antigen-6%C3%A2-months-after-radiation-with-androgen-deprivation-therapy-predicts-for-distant-metastasis-free-survival-and-prostate-cancer-specific-mortality
#7
Mihir Naik, Chandana A Reddy, Kevin L Stephans, Jay P Ciezki, Jorge Garcia, Petros Grivas, Andrew J Stephenson, Eric A Klein, Rahul D Tendulkar
OBJECTIVES/BACKGROUND: To determine whether a 6-month posttreatment prostate-specific antigen (PSA) value in patients with prostate cancer (PCa) treated with concurrent androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) serves as an early predictor for biochemical relapse free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific mortality (PCSM). METHODS: A retrospective review of intermediate-risk and high-risk PCa patients treated with EBRT and concurrent ADT at a single institution between 1996 and 2012...
November 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27670718/impact-of-single-agent-daily-prednisone-on-outcomes-in-men-with-metastatic-castration-resistant-prostate-cancer
#8
G Sonpavde, G R Pond, A J Templeton, E D Kwon, J S De Bono
BACKGROUND: Despite palliative benefits and PSA responses, the objective clinical impact of daily oral prednisone (P) for metastatic castration-resistant prostate cancer (mCRPC) is unknown. We performed a pooled analysis of control arms of randomized trials that either did or did not administer single-agent P to evaluate its impact on overall survival (OS) and toxicities. METHODS: Individual patient data from control arms of randomized trials of men with mCRPC who received placebo or P+placebo post docetaxel were eligible for analysis...
September 27, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27659411/the-use-of-68%C3%A2-ga-psma-pet-ct-in-men-with-biochemical-recurrence-after-definitive-treatment-of-acinar-prostate-cancer
#9
Greta Meredith, David Wong, John Yaxley, Geoff Coughlin, Les Thompson, Boon Kua, Troy Gianduzzo
INTRODUCTION: Early localisation of disease recurrence after definitive treatment of prostate cancer is vital to determine suitability for salvage treatment. Our aim was to further investigate the relationship between prostate specific antigen (PSA) level and detection of suspected cancer recurrence using (68 ) Ga-PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy (RP) or radiotherapy, particularly at low PSA levels. METHODS: This retrospective single tertiary referral institution cohort study of men reviewed the results of (68 ) Ga-PSMA PET/CT scans for investigation of post RP and post radiotherapy PSA recurrence following primary treatment of prostate cancer...
September 23, 2016: BJU International
https://www.readbyqxmd.com/read/27624889/targeting-protein-geranylgeranylation-slows-tumor-development-in-a-murine-model-of-prostate-cancer-metastasis
#10
Jacqueline E Reilly, Jeffrey D Neighbors, Raymond J Hohl
The isoprenoid biosynthetic pathway (IBP) plays a critical role in providing substrates and enzymes necessary for the post-translational modification and thus activation of a number of proteins involved in prostate cancer metastasis. Previous work by our lab found novel compound disodium [(6Z,11E,15E)-9-[bis(sodiooxy)phosphoryl]-17-hydroxy-2,6,12,16-tetramethyheptadeca-2,6,11,15-tetraen-9-yl]phosphonate (GGOHBP), which inhibits the IBP enzyme geranylgeranyl diphosphate synthase (GGDPS), reduced protein geranylgeranylation without altering protein farnesylation...
September 13, 2016: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/27614333/-very-early-salvage-radiotherapy-improves-distant-metastasis-free-survival
#11
Ahmed Abugharib, William C Jackson, Vasu Tumati, Robert T Dess, Jae Y Lee, Shuang G Zhao, Moaaz Soliman, Zachary S Zumsteg, Rohit Mehra, Felix Y Feng, Todd M Morgan, Neil Desai, Daniel E Spratt
PURPOSE: 'Early' salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer is commonly advocated in place of adjuvant radiotherapy. Herein, we aimed to determine the optimal definition of 'early' SRT. METHODS: A multi-institutional retrospective study of 657 men who underwent SRT between 1986-2013. Two comparisons were used to determine the optimal definition of early SRT; 1) Time from RP to SRT (<9, 9-21, 22-47, and >48 months), and 2) level of detectable pre-SRT PSA (0...
September 7, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27588490/micrornas-and-epithelial-mesenchymal-transition-in-prostate-cancer
#12
Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Rajvir Dahiya, Sharanjot Saini
Prostate cancer (PCa) is a leading cause of male cancer-related deaths. A significant fraction of prostate tumors are very aggressive, often metastasizing to bone, causing significant morbidity and mortality. Also, PCa is associated with high rates of recurrence, often attributed to the existence of cancer stem cells. Epithelial-mesenchymal transition (EMT), a process characterized by decreased expression of epithelial genes and increased expression of mesenchymal genes, plays a critical role in tumor invasion, metastasis and recurrence...
August 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/27575027/hsd3b1-and-resistance-to-androgen-deprivation-therapy-in-prostate-cancer-a-retrospective-multicohort-study
#13
Jason W D Hearn, Ghada AbuAli, Chad A Reichard, Chandana A Reddy, Cristina Magi-Galluzzi, Kai-Hsiung Chang, Rachel Carlson, Laureano Rangel, Kevin Reagan, Brian J Davis, R Jeffrey Karnes, Manish Kohli, Donald Tindall, Eric A Klein, Nima Sharifi
BACKGROUND: HSD3B1 (1245A>C) has been mechanistically linked to castration-resistant prostate cancer because it encodes an altered enzyme that augments dihydrotestosterone synthesis from non-gonadal precursors. We postulated that men inheriting the HSD3B1 (1245C) allele would exhibit resistance to androgen-deprivation therapy (ADT). METHODS: In this multicohort study, we determined HSD3B1 genotype retrospectively in men treated with ADT for post-prostatectomy biochemical failure and correlated genotype with long-term clinical outcomes...
October 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27518576/prostate-cancer-progression-and-mortality-a-review-of-diet-and-lifestyle-factors
#14
Sam F Peisch, Erin L Van Blarigan, June M Chan, Meir J Stampfer, Stacey A Kenfield
PURPOSE: To review and summarize evidence on the role of diet and lifestyle factors and prostate cancer progression, with a specific focus on habits after diagnosis and the risk of subsequent disease recurrence, progression, or death. METHODS: Given the well-documented heterogeneity of prostate cancer and the long survivorship of the majority of diagnoses, our goal was to summarize and describe modifiable risk factors for clinically relevant prostate cancer. We focused where possible on epidemiologic studies of post-diagnostic habits and prostate cancer progression, defined as recurrence (e...
August 12, 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27503809/metastatic-prostatic-adenocarcinoma-with-neuroendocrine-differentiation-to-meningioma
#15
Sahejmeet S Guraya, Richard A Prayson
The diagnosis of a tumor-to-tumor metastasis in the central nervous system most commonly involves metastasis to a meningioma. These combined lesions are often radiographically unsuspected and mimic a meningioma. Most commonly, the source of metastatic disease are carcinomas from the lung and breast. To our knowledge, fewer than a half dozen cases of metastatic prostatic adenocarcinoma to a meningioma have been documented in the literature. This report documents a 67-year-old man who presented with worsening confusion and altered mental status, accompanied by symptoms of increased urinary frequency, incontinence, and difficulty urinating...
August 5, 2016: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/27326657/what-s-new-in-screening-in-2015
#16
Sigrid V Carlsson, Monique J Roobol
PURPOSE OF REVIEW: The aim of this review was to highlight important articles in the field of prostate cancer screening published during 2015 and early 2016. Four major areas were identified for the purpose: screening strategies, post-United States Preventive Services Task Force (USPSTF) 2011-2012, screening trends/patterns, and shared decision making. RECENT FINDINGS: Several studies furthered the evidence that screening reduces the risk of metastasis and death from prostate cancer...
September 2016: Current Opinion in Urology
https://www.readbyqxmd.com/read/27184068/a-feasibility-study-showing-68-ga-citrate-pet-detects-prostate-cancer
#17
Spencer C Behr, Rahul Aggarwal, Youngho Seo, Carina M Aparici, Emily Chang, Kenneth T Gao, Dora H Tao, Eric J Small, Michael J Evans
PURPOSE: The management of advanced or recurrent prostate cancer is limited in part by the lack of effective imaging agents. Metabolic changes in prostate cancer have previously been exploited for imaging, culminating in the recent US FDA approval of [(11)C]choline for the detection of subclinical recurrent disease after definitive local therapy. Despite this milestone, production of [(11)C]choline requires an on-site cyclotron, limiting the scope of medical centers at which this scan can be offered...
May 16, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/27146024/metabolic-reprogramming-and-dependencies-associated-with-epithelial-cancer-stem-cells-independent-of-the-epithelial-mesenchymal-transition-program
#18
Esther Aguilar, Igor Marin de Mas, Erika Zodda, Silvia Marin, Fionnuala Morrish, Vitaly Selivanov, Óscar Meca-Cortés, Hossain Delowar, Mònica Pons, Inés Izquierdo, Toni Celià-Terrassa, Pedro de Atauri, Josep J Centelles, David Hockenbery, Timothy M Thomson, Marta Cascante
In solid tumors, cancer stem cells (CSCs) can arise independently of epithelial-mesenchymal transition (EMT). In spite of recent efforts, the metabolic reprogramming associated with CSC phenotypes uncoupled from EMT is poorly understood. Here, by using metabolomic and fluxomic approaches, we identify major metabolic profiles that differentiate metastatic prostate epithelial CSCs (e-CSCs) from non-CSCs expressing a stable EMT. We have found that the e-CSC program in our cellular model is characterized by a high plasticity in energy substrate metabolism, including an enhanced Warburg effect, a greater carbon and energy source flexibility driven by fatty acids and amino acid metabolism and an essential reliance on the proton buffering capacity conferred by glutamine metabolism...
May 2016: Stem Cells
https://www.readbyqxmd.com/read/27136742/efficacy-of-post-operative-radiation-in-a-prostatectomy-cohort-adjusted-for-clinical-and-genomic-risk
#19
A E Ross, R B Den, K Yousefi, B J Trock, J Tosoian, E Davicioni, D J S Thompson, V Choeurng, Z Haddad, P T Tran, E J Trabulsi, L G Gomella, C D Lallas, F Abdollah, F Y Feng, E A Klein, A P Dicker, S J Freedland, R J Karnes, E M Schaeffer
BACKGROUND: To date, there have been no published trials examining the impact of salvage radiation therapy (SRT) in the post-operative setting for prostate cancer (PCa). We conducted a retrospective, comparative study of post-operative radiation following radical prostatectomy (RP) for men with pT3 disease or positive margins (adverse pathological features, APF). METHODS: 422 PCa men treated at four institutions with RP and having APF were analyzed with a primary end point of metastasis...
September 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27102301/tissue-specific-conditional-pkc%C3%AE%C2%B5-knockout-mice-a-model-to-precisely-reveal-pkc%C3%AE%C2%B5-functional-role-in-initiation-promotion-and-progression-of-cancer
#20
Bilal Bin Hafeez, Louise Meske, Ashok Singh, Anupama Singh, Weixiong Zhong, Patricia Powers, Manorama John, Anne E Griep, Ajit K Verma
PKCε is a transforming oncogene and a predictive biomarker of various human cancers. However, a precise in vivo link of PKCε to cancer induction, progression and metastasis remain undefined. To achieve these goals, we generated tissue specific conditional PKCε knockout mice (PKCε-CKO) using cre-lox technology. Homozygous PKCε(LoxP/LoxP) mice have normal body weight and phenotype. To determine what effect loss of PKCε would have on the prostate, the PKCε(LoxP/LoxP) mice were bred to probasin cre (PB-Cre4+) mice which express cre specifically in the prostate epithelium of postnatal mice...
May 31, 2016: Oncotarget
keyword
keyword
76410
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"